ArticleArchives of rheumatology2026
An Evaluation of Factors Contributing to Primary Nonresponse to Biological Therapy in Patients with Spondyloarthropathy: A Retrospective Cohort Study.
Article in Archives of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsPrimary nonresponse to biological therapy in patients with spondyloarthropathy (SpA) is a considerable challenge. This study sought to identify the factors associated with primary nonresponse to biological therapy in a cohort of patients diagnosed with SpA. MATERIALS AND
methodsA retrospective analysis was performed on 261 patients with SpA who underwent at least 1 biological therapy. The incidence of primary nonresponse to any biological treatment was evaluated, and various clinical and demographic factors were analyzed for their potential associations with treatment outcomes.
resultsThe study found that the frequency of primary nonresponse to any biological disease-modifying antirheumatic drugs (bDMARDs) was 15.3% in the study population. In the logistic regression analysis of baseline parameters, presentation with arthritis at diagnosis was identified as a significant predictor of primary nonresponse (odds ratio: 2.113, 95% CI: 1.069-4.175, P = .031). Beyond this baseline predictor, primary non-responders significantly differed from responders by having higher frequencies of concomitant fibromyalgia (FMS) treatment (P = .047) and higher terminal C-reactive protein (CRP) levels (P = .030), as well as variations in acute-phase reactants, presence of psoriasis or enthesitis at diagnosis, and treatment-related factors such as bDMARDs duration.
conclusionThis study identifies baseline arthritis as a significant predictor of primary nonresponse to bDMARDs in SpA patients. Additionally, the presence of FMS and elevated CRP levels during follow-up are key clinical characteristics associated with the non-responder phenotype. These findings highlight the need for more objective assessment tools to distinguish true biological treatment failure from comorbid pain syndromes and the influence of disease phenotypes. Cite this article as: Oğuz Kökoğlu E, Kaplan H, Kızıltepe M, Kahraman Denizhan T, Cengiz CB, Şenel AS. An evaluation of factors contributing to primary nonresponse to biological therapy in patients with spondyloarthropathy: A retrospective cohort study. Arch Rheumatol. 2026;41(3):201-211.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.